STAT3 Stabilizes IKKα Protein through Direct Interaction in Transformed and Cancerous Human Breast Epithelial Cells by 송나영
cancers
Article
STAT3 Stabilizes IKKα Protein through Direct Interaction in
Transformed and Cancerous Human Breast Epithelial Cells
Young-Il Hahn 1,2, Soma Saeidi 1,2, Su-Jung Kim 2, Se-Young Park 3, Na-Young Song 3,*, Jie Zheng 2, Do-Hee Kim 4,
Han-Byoel Lee 5,6 , Wonshik Han 5,6 , Dong-Young Noh 5,6, Hye-Kyung Na 7 and Young-Joon Surh 1,2,5,*


Citation: Hahn, Y.-I.; Saeidi, S.; Kim,
S.-J.; Park, S.-Y.; Song, N.-Y.; Zheng, J.;
Kim, D.-H.; Lee, H.-B.; Han, W.; Noh,
D.-Y.; et al. STAT3 Stabilizes IKKα
Protein through Direct Interaction in
Transformed and Cancerous Human
Breast Epithelial Cells. Cancers 2021,
13, 82. https://doi.org/10.3390/
cancers13010082
Received: 15 December 2020
Accepted: 23 December 2020
Published: 30 December 2020
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional clai-
ms in published maps and institutio-
nal affiliations.
Copyright: © 2020 by the authors. Li-
censee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science
and Technology, Seoul National University, Seoul 08826, Korea; duddlf84@hotmail.com (Y.-I.H.);
saeidi@snu.ac.kr (S.S.)
2 Tumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National University,
Seoul 08826, Korea; nynna79@snu.ac.kr (S.-J.K.); jungle0621@naver.com (J.Z.)
3 Department of Oral Biology, Yonsei University College of Dentistry, Seoul 03722, Korea; SYPARK87@yuhs.ac
4 Department of Chemistry, College of Convergence and Integrated Science, Kyonggi University,
Suwon 16227, Korea; calla212@snu.ac.kr
5 Cancer Research Institute, Seoul National University, Seoul 03080, Korea; hblee.md@snu.ac.kr (H.-B.L.);
hanw@snu.ac.kr (W.H.); dynoh@snu.ac.kr (D.-Y.N.)
6 Department of Surgery, Seoul National University College of Medicine, Seoul 03080, Korea
7 Department of Food Science and Biotechnology, College of Knowledge-Based Services Engineering,
Sungshin Women’s University, Seoul 01133, Korea; nhk1228@sungshin.ac.kr
* Correspondence: nysong608@yuhs.ac (N.-Y.S.); surh@snu.ac.kr (Y.-J.S.)
Simple Summary: Signal transducer and activator of transcription 3 (STAT3) and nuclear factor-κB
(NF-κB) play a cooperative role in inflammation-associated tumorigenesis at multi-levels. The α
subunit of the inhibitor of the κB kinase (IKK) complex, IKKα, is involved in both classical and
non-classical activation of NF-κB. However, the interplay between STAT3 and IKKα has not been
clarified yet. Here, we report overexpression and co-localization of IKKα and STAT3 in human breast
cancer tissues as well as in human breast cancer cells, which promotes breast cancer promotion and
progression. IKKα was stabilized and upregulated by STAT3. We identified the lysine 44 residue of
IKKα as a putative binding site for STAT3. Taken together, these findings propose a novel mechanism
responsible for NF-κB activation by STAT3 through stabilization of IKKα. Thus, STAT3 and IKKα
could integrate, and coordinately mediate the growth and progression of human breast cancer.
Abstract: Signal transducer and activator of transcription 3 (STAT3) and nuclear factor-κB (NF-
κB) are two representative transcription factors that play a critical role in inflammation-associated
tumorigenesis through multi-level cooperation. Unlike other types of tumors, breast carcinomas
have shown a significant dependency on the non-classical NF-κB pathway as well as the classical one.
The α subunit of the inhibitor of the κB kinase (IKK) complex, IKKα, is involved in both classical
and non-classical activation of NF-κB. Although the cross-talk between STAT3 and NF-κB has been
suggested in several studies, the interplay between STAT3 and the regulators of NF-κB including
IKKα has not been fully clarified yet. In this study, we observed overexpression and co-localization
of IKKα and STAT3 in human breast cancer tissues as well as in H-Ras transformed human breast
epithelial (H-Ras MCF-10A) and breast cancer (MDA-MB-231) cells. By utilizing small interfering
RNA (siRNA) technology, we were able to demonstrate that STAT3 up-regulated IKKα, but not
IKKβ or IKKγ, in these cells. This was attributable to direct binding to and subsequent stabilization
of IKKα protein by blocking the ubiquitin-proteasome system. Notably, we identified the lysine
44 residue of IKKα as a putative binding site for STAT3. Moreover, siRNA knockdown of IKKα
attenuated viability, anchorage-independent growth and migratory capabilities of H-Ras MCF-10A
cells. Taken together, these findings propose a novel mechanism responsible for NF-κB activation by
STAT3 through stabilization of IKKα, which contributes to breast cancer promotion and progression.
Thus, breaking the STAT3-IKKα alliance can be an alternative therapeutic strategy for the treatment
of breast cancer.
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1. Introduction
Signal transducer and activator of transcription 3 (STAT3) and nuclear factor-κB (NF-
κB) are two principal transcription factors that play pivotal roles in inflammation-associated
tumorigenesis [1–3]. Constitutive activation or overexpression of both transcription factors
has been observed in a wide variety of malignancies, which strongly correlates to poor
prognostic outcomes in cancer patients [4,5]. Once activated, STAT3 and NF-κB induce
expression of genes involved in cell proliferation, transformation, and survival [3,6].
For both STAT3 and NF-κB, phosphorylation is an essential event required for their
activation. Upon phosphorylation at the tyrosine 705 residue, STAT3 dimerizes and mi-
grates to the nucleus for transactivation [6]. In the case of NF-κB, two distinct signaling
pathways, known as the classical (canonical) and the alternative (non-canonical) pathways,
account for its activation. For the classical pathway, phosphorylation of the inhibitor of
κB (IκBα) can lead to the release and nuclear localization of the p65/p50 heterodimer,
while the phosphorylation and subsequent processing of p100 into p52 are critical for
the alternative pathway [7]. The IκB kinase (IKK) complex, composed of IKKα, IKKβ
and IKKγ, is involved in directing phosphorylation of IκB. Among these, IKKα is solely
responsible for non-classical NF-κB activation through p100 phosphorylation [8].
Considering the shared characteristics in tumorigenesis and phosphorylation-
dependent regulation, it is anticipated that STAT3 and NF-κB can interact at multiple levels.
STAT3 has been reported to physically interact with p65, a functionally active subunit of
NF-κB, thereby retaining the latter transcription factor in the nucleus [9,10]. Activated
NF-κB, in turn, up-regulates the pro-inflammatory cytokines, such as interleukin-6 (IL-6),
a prototypic STAT3 activator [11], constituting a vicious cycle. Thus, STAT3 and NF-κB
sustain the pro-inflammatory and pro-tumorigenic microenvironment in a cooperative
manner [12,13].
The multi-level interactions between STAT3 and NF-κB have been elucidated par-
ticularly in the context of classical NF-κB activation, while the interplay between STAT3
and non-canonical NF-κB signaling has not been fully addressed. It is noteworthy that
both STAT3 and alternative NF-κB pathways are associated with poor prognosis in breast
cancer patients [14–16]. We have previously reported that inhibition of STAT3 can induce
apoptosis in H-Ras transformed human breast epithelial (H-Ras MCF-10A) cells [17], which
corroborates the crucial role of STAT3 in the progression of human breast carcinoma. In
the subsequent study, we observed the co-expression of STAT3 and IKKα in human breast
carcinoma tissues. This prompted us to more systematically explore the interplay between
STAT3 and IKKα and its implications for the growth and progression of breast cancer cells.
2. Results
2.1. IKKα Is Co-Expressed and Co-Localizes with STAT3 in Human Breast Carcinoma
We initially investigated the correlation between STAT3 and IKKα, particularly in the
context of the non-canonical NF-κB pathway, using specimens from patients with breast
carcinoma. As shown in Figure 1A, both IKKα and STAT3 were overexpressed in human
breast cancer tissues compared to their normal counterparts. The immunofluorescence
staining revealed that IKKα co-expressed and co-localized with STAT3 in tumors of human
breast cancer patients (Figure 1B). In conducting mechanistic studies, we initially examined
the IKKα expression level in H-Ras MCF-10A and human breast cancer MDA-MB-231 cells
as well as non-oncogenic MCF-10A cells. Both H-Ras MCF-10A and MDA-MB-231 cells
had abundant IKKα expression, compared to non-cancerous MCF-10A cells (Figure 1C
and Figure S1A). Consistently, immunofluorescence analysis revealed the relatively weak
co-expression as well as co-localization of STAT3 and IKKα in MCF-10A cells (Figure 1D),
whereas MDA-MB-231 cancer cells exhibited much stronger fluorescence intensity of both
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proteins (Figure 1E). Contrary to IKKα, the expression of IKKβ and IKKγ, the other subunits
of the IKK complex, was marginally increased in H-Ras MCF-10A cells (Figure S1B). In
line with this observation, the non-canonical NF-κB activation was escalated in IKKα-
overexpressing H-Ras MCF-10A cells compared to parental MCF-10A cells, as evidenced
by increased proteolysis of p100 to form p52 (Figure 1F). These results imply that STAT3 is
associated with a non-canonical NF-κB pathway via IKKα. Of note, STAT3 was activated
through phosphorylation in H-Ras MCF-10A and MDA-MB-231 cells (Figure 1C) as well as
human breast cancer tissues (Figure S1C) to a greater extent than their normal counterparts.
Figure 1. Co-expression of STAT3 and IKKα in human breast carcinoma. (A,B) Frozen sections from human breast carcinoma
and its normal adjacent tissues were stained with antibodies against STAT3 or IKKα. The representative images were
obtained by immunohistochemical (A) and immunofluorescence (B) analyses. 4′,6-Diamidino-2-phenylindole (DAPI),
nuclear staining for immunofluorescence. Scale bar, 100 µm. (C) Immunoblot analysis shows comparative expression levels
of IKKα, phospho-STAT3 (p-STAT3) and STAT3 in MCF-10A, H-Ras MCF-10A, and MDA-MB-231 cells. Actin was used as
an equal loading control. (D,E) Immunofluorescence analysis of IKKα and STAT3 in MCF-10A (D) and MDA-MB-231 (E)
cells. DAPI, nuclear staining for immunofluorescence. Scale bar, 200 µm. (F) Immunoblot analysis showing comparative
expression levels of IKKα, p100, and its cleaved form p52 in MCF-10A and H-Ras MCF-10A cells.
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2.2. IKKα May Promote Human Breast Cancer Progression through Non-Canonical
NF-κB Activation
Based on the observation of the co-expression and co-localization of IKKα and STAT3,
we speculated that IKKα might also play a role in the progression of human breast car-
cinoma, as STAT3 does. To test this supposition, a survival analysis was performed by
examining the expression levels of the IKK isoforms using the Xena browser dataset for
breast cancer. In a breast cancer cohort, the patient group with high IKKα expression exhib-
ited worse overall survival, particularly at the late stage, compared to the low IKKα group
(Figure S2A). However, there was no obvious correlation between the overall survival and
the expression levels of the other two subunits of the IKK complex (Figure S2B,C). These
findings suggest that IKKα overexpression is associated with poor prognosis in breast
carcinoma.
To further assess the role of IKKα in the progression of breast carcinoma, the gene
silencing strategy using a siRNA against IKKα was adopted. As depicted in Figure 2A,
IKKα knockdown reduced the expression of representative pro-inflammatory genes (COX-
2, IL-6, and IL-8), which is under the control of both STAT3 and NF-κB [18,19], in H-Ras
MCF-10A cells. Furthermore, the siRNA knockdown of IKKα markedly suppressed the
colony forming (Figure 2B,C) and migratory (Figure 2D,E) abilities of H-Ras MCF-10A
and MDA-MB-231 cells, respectively. These data indicate that IKKα exerts pro-oncogenic
functions by stimulating the alternative NF-κB pathway in breast cancer.
2.3. STAT3 Regulates IKKα Expression in H-Ras Transformed and Cancerous Human Breast
Epithelial Cell Lines
The co-expression and coordinated oncogenic functions of IKKα and STAT3 imply a
cross-talk between these two signaling proteins in human breast carcinoma. In order to
clarify this implication, cells were transfected with a siRNA against either IKKα or STAT3.
The silencing of IKKα was not able to alter the expression of STAT3 in H-Ras MCF-10A
(Figure 3A), MDA-MB-231 (Figure 3B), and MCF-7 (Figure S3A) cells. However, STAT3
knockdown significantly reduced the expression of IKKα in H-Ras MCF-10A (Figure 3C
and Figure S3B), MDA-MB-231 (Figure 3D), and MCF7 (Figure S3A) cells. On the contrary,
the ectopic expression of STAT3 elevated the IKKα expression level in human breast cancer
MCF7 cells (Figure 3E), lending further support to the notion that STAT3 up-regulates IKKα
expression. In addition to siRNA directed to silence STAT3, treatment with Stattic, a small
molecule known to selectively inhibit the STAT3 activation [20], down-regulated IKKα
protein expression (Figure 3F) without altering IKKα mRNA expression (Figure S3C). These
findings suggest that not only STAT3 expression, but also its activity is important for IKKα
regulation. Notably, neither genetic nor pharmacologic inhibition of STAT3 changed the
expression levels of IKKβ and IKKγ (Figure 3C,D,F). However, STAT3 silencing blocked
proteolysis of p100, a marker of alternative NF-κB activation, in H-Ras MCF-10A cells
(Figure S3D), further supporting the role for STAT3 in IKKα-mediated non-canonical NF-
κB activation. Taken together, these results suggest that STAT3 specifically up-regulates the
protein expression of the α subunit in the IKK complex, a key player in the non-canonical
NF-κB pathway.
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Figure 2. IKKα knockdown suppresses tumorigenesis in H-Ras MCF-10A and MDA-MB-231 cells. (A) RT-PCR analysis
of IKKα, IL-6, IL-8, and COX-2 mRNA expression in H-Ras MCF-10A cells transfected with si-Control or si-IKKα for
48 h. GAPDH, an equal loading control for PCR. (B,C) H-Ras MCF-10A (B) and MDA-MB-231 (C) cells were plated in
a 6-well plate and incubated with si-Control or si-IKKα for 7 days. Then, the colonies were stained with 0.5% crystal
violet. The number of colonies was counted and presented as a bar graph. ** p < 0.01 (n = 3). (D,E) H-Ras MCF-10A (D)
and MDA-MB-231 (E) cells were seeded in an ibidi culture insert and then transfected with si-Control or si-IKKα for 48 h.
The progression of cell migration was visualized under the microscope and presented as a bar graph. ns, not significant;
* p < 0.05; ** p < 0.01; *** p < 0.001 (n = 3).
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Figure 3. STAT3-dependent expression of IKKα in human breast cancer cell lines. (A,B) Immunoblot
analysis of IKKα and STAT3 in H-Ras MCF-10A (A) and MDA-MB-231 (B). Cells were transfected
with si-Control or si-IKKα for 48 h, and expression of STAT3 was measured by immunoblot analysis.
Actin, a loading control for immunoblotting. For Figure 3A, the band intensities were normalized by
the actin level and presented as bar graphs. ns, not significant; ** p < 0.01; *** p < 0.001 (n = 3). (C,D)
Immunoblot analysis of STAT3, IKKα, IKKβ, and/or IKKγ expression levels in H-Ras MCF-10A
(C) and MDA-MB-231 (D) cells transfected with si-Control or si-STAT3 (5 and 20 nM) for 48 h. For
Figure 3C, the band intensities were normalized by the actin level and presented as bar graphs.
ns, not significant; ** p < 0.01 (n = 3). (E) Immunoblot analysis of IKKα and STAT3 in MCF7 cells
transfected with mock or STAT3-overexpressing vectors. (F) The H-Ras MCF-10A cells were treated
with Stattic (1 µM) for 6 or 12 h. The expression levels of p-STAT3, IKKα, IKKβ, and IKKγ were
assessed by immunoblot analysis. The band intensities were normalized by the actin level and
presented as bar graphs. ns, not significant; * p < 0.05; ** p < 0.01 (n = 3).
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2.4. STAT3 Stabilizes IKKα Protein in H-Ras MCF-10A Cells
Next, we investigated how STAT3 up-regulates IKKα expression. While both siRNA
knockdown (Figure 3C) and pharmacologic inhibition (Figure 3F) of STAT3 reduced the
expression of IKKα protein, there was no alteration in the expression levels of its mRNA
transcript in H-Ras MCF-10A cells (Figure 4A and Figure S3C). Furthermore, the cyclo-
hexamide (CHX) chase assay showed that the half-life of the IKKα protein was markedly
declined by STAT3 silencing in H-Ras MCF-10A cells (Figure 4B). Thus, it is likely that
STAT3 stabilizes IKKα protein, rather than promoting its de novo synthesis. In support of
this assumption, a proteasome inhibitor MG132 fully restored IKKα protein expression,
which was abolished by STAT3 knockdown (Figure 4C). However, blocking either the
expression (Figure 4D) or activity (Figure 4E) of STAT3 enhanced the poly-ubiquitination of
IKKα in H-Ras MCF-10A cells. Thus, STAT3 protects IKKα from the ubiquitin-dependent
proteasomal degradation, resulting in the stabilization and accumulation of IKKα.
Figure 4. STAT3 protects IKKα from ubiquitin-dependent proteasomal degradation in H-Ras MCF-
10A cells. (A) RT-PCR analysis of STAT3 and IKKα mRNA expression in H-Ras MCF-10A cells
transfected with si-Control or si-STAT3 (5 and 20 nM) for 48 h. The bar graphs show the relative
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intensities of STAT3 (bottom panel, left) and IKKα (bottom panel, right) measured by densitometry
analyses. GAPDH, an equal loading control for PCR. ns, not significant; ** p < 0.01; *** p < 0.001
(n = 3). (B) The H-Ras MCF-10A cells were incubated with si-Control or si-STAT3 for 24 h, followed
by treatment with CHX (20 µg/mL) for various time points. The expression of STAT3 and IKKα
was analyzed by immunoblot analysis (upper) and the relative intensity of IKKα was measured
and plotted over time (bottom). * p < 0.05 (n = 3). (C) H-Ras MCF-10A cells were pre-incubated
with si-Control or si-STAT3 for 48 h and then treated with MG132 (10 µM) for an additional 2 h.
The expression levels of STAT3 and IKKα were analyzed by immunoblot analysis (upper), and the
band intensities were normalized and presented as a bar graph (bottom). * p < 0.05; ** p < 0.01;
*** p < 0.001 (n = 3). (D) Immunoprecipitation analysis showing ubiquitination of IKKα. H-Ras
MCF-10A cells treated with MG132 for 2 h after pre-incubation with si-Control or si-STAT3 for 48 h.
Immunoprecipitation was performed with an IKKα antibody and then the immunocomplexes were
gel-separated and blotted with IKKα or ubiquitin antibodies. (E) Immunoblot analysis of IKKα
expression and ubiquitination in H-Ras MCF-10A cells exposed to MG132 for 2 h post-treatment
with or without Stattic (1 µM) for 48 h. Immunoprecipitation was performed with an IKKα antibody,
followed by immunoblotting with a ubiquitin or an IKKα antibody.
2.5. STAT3 Physically Interacts with IKKα, Presumably at Lys44
It has been reported that IKKα protein stability is enhanced through physical in-
teraction with other proteins, such as Hsp90 and Cdc37 [21,22]. As IKKα and STAT3
co-localized in human breast cancer patient tissues as well as human breast cancer cell
lines (Figure 1C,E,F), we speculated that STAT3 could stabilize IKKα protein through phys-
ical interaction. The direct interaction between STAT3 and IKKα was evident in H-Ras
MCF-10A cells, which was revealed by co-immunoprecipitation (Figure 5A) and an in situ
proximity ligation assay (PLA) (Figure 5B). The exogenous interaction between STAT3 and
IKKα was also assessed in HEK293T (Figure 5C) and MCF-10A (Figure S4A) cells after
ectopic expression of both proteins. The physical interaction between STAT3 and IKKα
was also confirmed in MDA-MB-231 cells by PLA (Figure 5D). Again, STAT3 was not able
to directly interact with IKKβ and IKKγ (Figure S4B). These data clearly show that STAT3
specifically binds to the α subunit of IKK complex, other than β or γ subunits.
Previously, Xiao et al. have demonstrated that the lysine 44 residue within the kinase
domain of IKKα is crucial for its protein stability [23]. Thus, we speculated that STAT3
might physically bind to the lysine 44 of IKKα protein to prevent its degradation. Mutation
of lysine 44 to alanine (K44A) on IKKα interrupted its interaction with STAT3 in both
H-Ras MCF-10A (Figure 5E) and HEK293T (Figure 5F and Figure S4C) cells. The PLA assay
further confirmed that K44A mutation in IKKα abolished its interaction with STAT3 in
HEK293T cells (Figure 5G). All these data, taken together, support that STAT3 directly binds
to IKKα, particularly at lysine 44, and thereby enhances its protein stability by blocking the
ubiquitin-dependent proteasomal degradation. This STAT3-dependent IKKα stabilization
can further escalate tumorigenesis in human breast carcinoma through the non-canonical
activation of NF-κB.
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Figure 5. STAT3 directly interacts with IKKα in vitro. (A,C) IP analysis showing a physical interaction between IKKα and
STAT3 in H-Ras MCF-10A (A) and HEK293T (C) cells. Immunoprecipitation was performed with IKKα (left) or STAT3
(right) antibodies, followed by immunoblotting with antibodies for STAT3 and IKKα, respectively. IgG, a negative control
for immunoprecipitation; input, total protein lysate. (B,D) Duolink analysis showing the interaction between STAT3 and
IKKα in H-Ras MCF-10A (B) and MDA-MB-231 (D) cells. The representative image was visualized under the fluorescent
microscope. (E,F) H-Ras MCF-10A (E) and HEK293T (F) cells were transfected with IKKα wild type (WT) or K44A mutant
(K44A) in the presence of STAT3 construct for 48 h, followed by MG132 treatment for additional 2 h. Immunoprecipitation
analysis showing the interaction between STAT3 and either WT or K44A IKKα. (G) Duolink analysis showing the STAT3
binding to IKKα WT or K44A mutant in HEK293T cells.
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3. Discussion
STAT3 and NF-κB are the major transcription factors known to regulate the expression
of genes involved in immune responses, cell proliferation, and survival, linking inflam-
mation and carcinogenesis [24]. Constitutive activation of STAT3 or NF-κB up-regulates
major pro-inflammatory cytokines, such as TNFα, IL-1, and IL-6, which can promote cancer
cell proliferation, angiogenesis, and metastasis [2,25,26]. Furthermore, STAT3 conditional
knockout mice were found to be less susceptible to chemically induced skin [27] and
colon [28] carcinogenesis. Similarly, either IKKβ ablation or p65 deficiency suppresses
tumorigenesis in these mouse models, implying that STAT3 and NF-κB phenocopy each
other peculiarly in the context of promoting tumorigenesis [12,29,30].
By examining the data in the catalogue of somatic mutations in cancer (COSMIC),
Kaltschmidt et al. have found that IKKα is highly up-regulated in human breast cancer
tissues, compared to other types of cancers [31]. This implies that in mammary tumors, the
non-classical NF-κB pathway is more likely to play a principal role in the oncogenic signal
transduction than the classical pathway. In agreement with this notion, up-regulation of
either IKKα or p100 is associated with poor survival in the breast cancer patients [14,16].
We also observed that the expression of IKKα, rather than IKKβ or IKKγ, was positively
correlated with poor prognosis, according to the Xena browser in TCGA BRCA database
(Figure S2). Moreover, it has been reported that the mammary gland-specific p100 over-
expression induces the up-regulation of the pro-tumorigenic proteins in mice [32]. With
regard to uncovering the novel therapeutic targets and/or strategies to treat breast carcino-
mas, it would be worthwhile to understand how STAT3 interacts with the non-canonical
NF-κB pathway.
STAT3 and NF-κB collaborate at several different levels. Some of the pro-inflammatory
genes, such as COX-2 and IL-6, contain the binding sites for both STAT3 and NF-κB in their
promoter regions, allowing an interdependent regulation [12,13]. Moreover, STAT3 has
been reported to physically interact with RelA/p65 and p50 subunits of NF-κB, particularly
responsible for the classical activation of NF-κB [9,10,33]. In addition to the direct binding,
STAT3 can mediate sustained nuclear localization of RelA/p65, resulting in a prolonged
activation of the canonical NF-κB signaling [9]. However, how STAT3 interplays with
the non-canonical NF-κB pathway has remained elusive, although the alternative NF-κB
activation also takes an important role in the inflammation and tumorigenesis.
In the current study, STAT3 was found to regulate the protein expression of IKKα, but
not that of IKKβ or IKKγ, in H-Ras MCF-10A cells and MDA-MB-231 breast cancer cells.
The silencing of IKKα remarkably suppressed proliferative and migratory abilities of these
cells. While IKKβ and γ do not play much of a role in the non-classical activation, IKKα
is well known to be involved in both classical and non-classical NF-κB pathways [34]. In
our study, IKKα triggered the non-canonical NF-κB activation in H-Ras MCF-10A cells in
which STAT3 signaling is overactivated. Thus, our findings strongly support that STAT3
is closely inter-connected with the alternative NF-κB pathway via IKKα regulation. We
also noticed that STAT3 directly interacted with IKKα and stabilized it by inhibiting the
ubiquitin-dependent proteasomal degradation (Figure 6). Xiao et al. have shown that
IKKα mutation on K44A facilitates its protein degradation, indicating that the lysine 44 is
important to maintain IKKα protein stability [23]. Interestingly, we found that STAT3 failed
to form a complex with the IKKα K44A mutant. This may explain why the IKKα K44A
mutant is vulnerable to degradation. The lysine 44 of the IKKα protein provides a contact
point to STAT3, which contributes to the stabilization of IKKα. Further investigation is
required to fully elucidate the underlying mechanism.
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Figure 6. A proposed scheme of the interaction between STAT3 and IKKα. STAT3 directly interacts
with and stabilizes IKKα, thereby regulating non-canonical NF-κB signaling.
4. Materials and Methods
4.1. Tissues, Cell Culture, and siRNA Knockdown of Gene Expression
Human breast cancer tissue slides (including both adjacent and malignant tissues; a
total of three pairs) were obtained from the biorepository of Lab of Breast Cancer Biology
at the Cancer Research Institute, Seoul National University. Non-transformed human
mammary epithelial MCF-10A (ATCC: CRL-10317) cells and H-Ras MCF-10A (obtained
from Prof. Aree Moon of Duksung Women’s University) cells were grown in DMEM/F-12
supplemented with 5% horse serum, 100 ng/mL cholera toxin, 20 ng/mL human epi-
dermal growth factor, 10 µg/mL insulin, 0.5 µg/mL hydrocortisone, 2 mM L-glutamine,
and 100 units/mL penicillin/streptomycin. Human embryonic kidney HEK293T cells
(ATCC: CRL-11268) and human breast cancer MDA-MB-231 (ATCC: HTB-26) and MCF-7
(ATCC: HTB-22) cell lines were maintained in DMEM and RPMI 1640 supplemented with
10% fetal bovine serum and 100 units/mL penicillin/streptomycin. For gene silencing
experiments, cells were transfected with siRNA for human STAT3 (target sequence
5′-CUAUCUAAGCCCUAGGUUUdTdT-3′ and 5′-CCUAGGGCUUAGAUAGdTdT-
3′), human IKKα (target sequences 5′-GAAGAAAUGGCUAUGAACAdTdT-3′ and
5′-UGUUCAUAGCCAUUUCUUCdTdT-3′), or scrambled negative control (target se-
quence 5′- CCUACGCCACCAAUUUCGU-3′, and 5′-ACGAAAUUGGUGGCGUAGG-3′)
using the Lipofectamine RNAi-MAX transfection reagents according to the instructions
supplied by the manufacturer (Invitrogen; Carlsbad, CA, USA). Each siRNA was diluted
in serum-free media in a final volume of 6 µL. Transfection reagents diluted in serum-free
media in a final volume of 10 µL were added to each well. After a 30-min incubation at
room temperature, cells were added to the plates. After 48-h transfection, cells were lysed
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for further analysis. We custom prepared those siRNAs from Bioneer (Seoul, Korea). For
ectopic expression of STAT3 and IKKα, cells were transfected with STAT3 overexpression
vector pCMV-HA-STAT3 plus pcDNA3-IKKa WT or mutant (K44A) plasmid.
4.2. Reagents and Antibodies
Recombinant human IL-6 and MG132 were purchased from R&D Systems, Inc. (Min-
neapolis, MN, USA). CHX was purchased from Sigma Aldrich (St. Louis, MO, USA).
Primary antibodies for p-STAT3Y705, STAT3, IKKα, IKKβ, IKKγ, p100, HA-tag (anti-rabbit),
and His-tag (rabbit) were purchased from Cell Signaling Technology (Danvers, MA, USA).
Primary antibody against His-tag (mouse) was purchased from Santa Cruz Biotech (Santa
Cruz, CA, USA). An anti-ubiquitin antibody was obtained from Thermo Fisher Scientific
(Waltham, MA, USA). DAPI was purchased from Invitrogen.
4.3. Public Data Resources and Survival Analysis
The Kaplan-Meier plots of the five-year overall survival were generated by the USCS
Xena browser (https://xenabrowser.net) in TCGA BRCA database. The patients were
divided into high and low IKKα/IKKβ/IKKγ gene expression groups according to median
expression.
4.4. Immunoblot and Immunoprecipitaion Assays
For immunoblot analysis, cell lysates were heated for 5 min at 95 ◦C in the protein
gel-loading buffer, and applied to 7–12% sodium dodecyl sulfate-polyacrylamide gels.
The separated proteins were transferred to a PVDF membrane, blocked in 5% nonfat
milk, and analyzed using the specific primary antibodies. Proteins were detected using a
chemiluminescence reagent. For immunoprecipitation, cell lysates were first treated with
STAT3 antibody or IKKα antibody at 4 ◦C overnight using a rotator, followed by incubation
with protein A/G beads (Santa Cruz Biotech). The immunoprecipitates were washed with
lysis buffer three times and subjected to IB with indicated antibodies. The band intensity
was measured using Gel-Pro Analyzer™ software and normalized with the loading control.
All original blot images were shown in Figures S5–S13.
4.5. Immunohistochemistry and Immunofluorescence Staining
Paraffin-embedded tissues were deparaffinized with xylene. For antigen retrieval,
tissues were heated in a microwave oven with citrate buffer (DakoCytomation; Glostrup,
Denmark). The tissue sections were incubated with 0.2% Triton X-100 for permeabilization,
then blocked with 3% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for
1 h. Then, the sections were incubated overnight at 4 ◦C with specific primary antibodies,
followed by incubation with secondary antibodies conjugated with horse radish peroxi-
dase for immunohistochemistry, or conjugated with fluorophore for immunofluorescence
staining. For immunofluorescence staining, H-Ras MCF-10A cells were cultured (2 × 104
in an eight-chamber slide), fixed with 95% methanol/5% acetic acid for 10 min and per-
meabilized with 0.2% Triton X-100 for 5 min. The cells were then blocked with 5% BSA
in PBS with Tween 20 (PBS-T) for 1 h and incubated with specific primary antibodies in
PBS-T containing 1% BSA at 1:100 dilution at 4 ◦C overnight, followed by staining with
Alexa Fluor secondary antibodies (Invitrogen). Finally, the slides were mounted with DAPI
(Invitrogen) and visualized under a florescent microscope.
4.6. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen). The cDNA was synthe-
sized from the isolated RNA with a reverse transcriptase (Promega; Madison, WI, USA),
according to the manufacturer’s instruction. For PCR, primers included the following: IKKα,
5′- AGTTCTTCAGGATGTTGGTGG-3′ and 5′-CCAGACACATAGTGCACTGCT-3′; STAT3,
5′- AGAATCACGCCTTCTACAGACTG-3′ and 5′-ACGATTCTCTCCTCCAGCATC-3′; COX-
2, 5′-GCTGAGCCATACAGCAAATCC-3′ and 5′-GGGAGTCGGGCAATCATCAG-3′; IL-6,
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5′-GTGTGAAAGCAGCAAAGAGGC-3′ and 5′-CTGGAGGTACTCTAGGTATAC-3′; and IL-8,
5′-ATGACTTCCAAGCTGGCCGTGGCT-3′ and 5′-TCTCAGCCCT CTTCAAAAACTTCT-3′.
4.7. Soft Agar Colony Forming and Migration Assays
For the soft agar colony forming assay, cells (1 × 105) were added to media containing
3.3% agarose and layered onto a 60 mm2-dish containing 0.5% agar in DMEM/F12 media.
The cells were incubated with indicated siRNAs for 7 days. Once a colony formed, the
colonies were fixed in cold methanol and stained with crystal violet. The colonies were
visualized under a microscope (Nikon) and quantified. For the migration assay, cells were
seeded onto Culture-Inserts® (ibidi; Regensburg, Germany) to generate a wound gap.
After incubation with indicated siRNAs for 8 or 24 h, the insert was gently removed. The
progression of wound closure was visualized at various time points under the microscope.
4.8. CHX Chase Assay
H-Ras MCF10A cells were transfected with scrambled or STAT3 siRNAs. At 24 h
post-transfection, cells were treated with CHX (20 µg/mL) at various time points from
0 to 3 h. Then, the cells were harvested and lysed. The cell lysates were subjected to
immunoblot analysis with STAT3 and IKKα antibodies to determine the half-life of IKKα
protein.
4.9. PLA
PLA was performed using the DUOLinkTM kit (OLINK; Uppsala, Sweden). H-Ras
MCF-10A and MDA-MB-231 cells were seeded onto the glass slide and incubated for 24 h.
After incubation, the cells were washed with PBS, fixed with 95% methanol/5% acetic acid
for 10 min, permeabilized with 0.2% Triton X-100 for 5 min and again washed with PBS
three times. Cells were then blocked with 5% BSA in PBS-T for 1 h and incubated with
anti-STAT3 and anti-IKKα in PBS-T containing 1% BSA at 1:100 dilution at 4 ◦C overnight.
After incubation, the cells were washed with PBS-T and then incubated with PLA plus and
minus affinity probes for 1 h at 37 ◦C. The probes were then hybridized with a ligase. The
DNA was amplified and detected under the fluorescence microscopy.
4.10. Statistical Analysis
All experiments were performed in triplicate and repeated three times. Difference
between groups was analyzed by Student’s unpaired t-test. The data were presented as
means ± standard deviations (S.D.) of at least three independent repeats. The values of p
less than 0.05 were considered to indicate statistical significance.
5. Conclusions
STAT3 stabilizes and up-regulates IKKα expression, responsible for the non-canonical
NF-κB activation, in H-Ras MCF-10A cells, exacerbating tumorigenesis (Figure 6). The
STAT3-IKKα interaction plays a crucial role for IKKα stabilization, which can provide a
novel therapeutic target for breast cancer treatment. Thus, STAT3 could integrate between
both distinct NF-κB signaling pathways, which coordinately mediates the inflammation-
associated carcinogenesis in human breast carcinomas. However, further studies will be
necessary to clarify the molecular and cellular contexts in which STAT3 determines its
oncogenic partner between canonical and non-canonical NF-κB pathways.
Supplementary Materials: The following materials are available online at https://www.mdpi.com/
2072-6694/13/1/82/s1. Figure S1: Protein expression levels of IKK isoforms and pSTAT3 in human
breast carcinoma tissues and cell lines; Figure S2: Survival analyses based on the expression of IKK
isoforms in human breast cancer cohort; Figure S3: STAT3-dependent expression of IKKα in human
breast cancer cell lines; Figure S4: STAT3 is not able to interact with other IKK subunits; Figure S5:
The original blot images of Figure 1; Figure S6: The original blot images of Figure 2; Figure S7: The
original blot images of Figure 3A,B; Figure S8: The original blot images of Figure 3C,D; Figure S9: The
original blot images of Figure 3E,F; Figure S10: The original blot images of Figure 4A,B; Figure S11:
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The original blot images of Figure 4C,D; Figure S12: The original blot images of Figure 5; Figure S13:
The original blot images of Figures S1 and S3.
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